Premium
NIVOLUMAB COMBINED WITH BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA: EFFICACY AND SAFETY FROM THE PHASE 2 CHECKMATE 436 STUDY
Author(s) -
Zinzani P.L.,
Santoro A.,
Gritti G.,
Brice P.,
Barr P.M.,
Kuruvilla J.,
Cunningham D.,
Kline J.,
Johnson N.A.,
MehtaShah N.A.,
Manley T.,
Francis S.,
Sharma M.,
Moskowitz A.J.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.114_2629
Subject(s) - brentuximab vedotin , nivolumab , medicine , cd30 , lymphoma , oncology , refractory (planetary science) , anaplastic large cell lymphoma , transplantation , phases of clinical research , chemotherapy , gastroenterology , immunotherapy , cancer , physics , astrobiology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom